Dermal inflammation in psoriatic arthritis, the association to molecular mass of hyaluronan and effect of adalimumab. A prospective, open-label, multi-center study of hyaluronan molecular mass distribution in psoriatic arthritis patients compared to healthy subjects.

Trial Profile

Dermal inflammation in psoriatic arthritis, the association to molecular mass of hyaluronan and effect of adalimumab. A prospective, open-label, multi-center study of hyaluronan molecular mass distribution in psoriatic arthritis patients compared to healthy subjects.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Aug 2013

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 17 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top